Spots Global Cancer Trial Database for arx788
Every month we try and update this database with for arx788 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ARX788 in Breast Cancer With Low Expression of HER2 | NCT05018676 | Breast Cancer W... | ARX788 | 18 Years - 75 Years | Fudan University | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | NCT06224673 | HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto... | ARX788 Computed Tomogr... Biospecimen Col... | 18 Years - | University of California, San Francisco | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | NCT04829604 | HER2 Positive M... | ARX788 | 18 Years - | Ambrx, Inc. | |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | NCT04829604 | HER2 Positive M... | ARX788 | 18 Years - | Ambrx, Inc. | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | NCT05041972 | HER2 Mutation-R... HER2 Amplified ... | ARX788 | 18 Years - | Ambrx, Inc. | |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | NCT05426486 | HER2-positive B... | ARX788 Pyrotinib malea... Trastuzumab Pertuzumab Docetaxel Carboplatin | 18 Years - 75 Years | Shengjing Hospital | |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | NCT05426486 | HER2-positive B... | ARX788 Pyrotinib malea... Trastuzumab Pertuzumab Docetaxel Carboplatin | 18 Years - 75 Years | Shengjing Hospital | |
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | NCT03255070 | Breast Neoplasm... Gastric Neoplas... Solid Tumors | ARX788 | 18 Years - | Ambrx, Inc. | |
| ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases | NCT05018702 | HER2-positive, ... | ARX788 | 18 Years - 75 Years | Fudan University | |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | NCT06224673 | HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto... | ARX788 Computed Tomogr... Biospecimen Col... | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
